AI assistant
Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021
Jun 18, 2021
31511_dirs_2021-06-17_20f6f2d8-fc1b-442c-a90b-3923a309e1c7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-06-15
Reporting Person: Goldberg Andrew D. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-15 | Stock Option (right to buy) | $35.26 | A | 7500 | Acquired | 2031-06-15 | Common Stock (7500) | Direct |
| 2021-06-15 | Stock Option (right to buy) | $35.26 | A | 10000 | Acquired | 2031-06-15 | Common Stock (10000) | Direct |
Footnotes
F1: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.